Stcube 

STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a technology designed to screen for antibodies that selectively mask specific sites of target proteins; and Glyco-Specific Antibody Characterization and Optimization Platform, a technology designed to optimize characteristics exerted by antibodies that mask specific sites of target proteins. The company's product pipeline consists of various anti-cancer drugs, including programmed death ligand 1, a type of protein, which is expressed in cancer cells and interferes with the natural tumor killing of immune cells; programmed death-1, a type of protein that is expressed in T cells; and cytotoxic T-lymphocyte associated protein 4, a protein that inhibits the activity of T-cells that can kill cancer cells. Its product pipeline also comprises lymphocyte-activation gene 3, a type of protein, which exists in the cell membrane of immune cells, such as T-cells and NK cells. The company was formerly known as Schem Co., Ltd. and changed its name to STCube, Inc. in April 2008. STCube, Inc. was founded in 1989 and is headquartered in Seoul, South Korea.